UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16 under

the Securities Exchange Act of 1934

For the month of June, 2023

Commission File Number 001-39670

PURETECH HEALTH PLC

(Translation of registrant’s name into English)

6 Tide Street, Suite 400

Boston, Massachusetts 02210

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F  ☒             Form 40-F  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):  ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):  ☐

INFORMATION CONTAINED IN THIS REPORT ON FORM 6-K

The attached letters were delivered to shareholders of PureTech Health plc (LSE: PRTC, Nasdaq: PRTC) (the “Company”).

The press release is furnished herewith as Exhibit 99.1 and Exhibit 99.2 and is incorporated by reference herein.

Exhibits

99.1    Cover letter from the Company to its shareholders

99.2    Letter from KPMG to the shareholders of the Company

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Exhibit 99.1

PureTech Health plc 6 Tide Street, Suite 400, Boston, MA 02210 Tel 617.482.2333 Fax 617.482.3337 puretechhealth.com

This letter is being sent to the shareholders of PureTech Health plc (the ‘Company’) for information only and no action is required to be taken. If you have sold or transferred all of your ordinary shares in the Company you should pass this document to the purchaser or transferee or to the person through whom the sale was effected for transmission to the purchaser or transferee.

9 June 2023

Dear Shareholder

CHANGE OF AUDITOR

As explained in this year’s Notice of Annual General Meeting, following a formal and comprehensive tender process, the Audit Committee recommended to the Board the appointment of PricewaterhouseCoopers LLP as the preferred new auditor. Based on this recommendation, the Board is proposing that PricewaterhouseCoopers LLP be appointed as external auditor of the Company pursuant to a resolution to be proposed at the Annual General Meeting that is due to be held on 13 June 2023.

KPMG LLP has consequently resigned as auditor of the Company effective from 31 May 2023. We are required by section 520(2) of the Companies Act 2006 to send a copy of KPMG LLP’s resignation statement to shareholders. A copy of the statement is set out overleaf.

This letter needs no action on shareholders’ part but is provided to you in fulfilment of a statutory obligation upon the Company.

Yours faithfully

Bharatt Chowrira

Director and Company Secretary

PureTech Health plc is a public limited company incorporated in England & Wales under company number 09582467. Registered office: 8th Floor, 20 Farringdon Street, London EC4A 4AB, United Kingdom.

Exhibit 99.2

Private & confidential

PureTech Health plc

8th Floor

20 Farringdon Street London

EC4A 4AB

31 May 2023

Dear Sir/Madam,

Statement to PureTech Health plc (no. 09582467) on ceasing to hold office as auditors pursuant to section 519 of the Companies Act 2006

The reason connected with our ceasing to hold office is the holding of a competitive tender for the audit, in which we were unsuccessful in retaining the audit.

Yours faithfully,

KPMG LLP

Audit registration number: 9188307

Audit registration address:

15 Canada Square

Canary Wharf, London E14 5GL